Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Even If Cannabis Recovers, Aurora Stock Is a Terrible Bet

By Todd Shriber, InvestorPlace Contributor
That's one way of saying Aurora is again proving to be a value destroyer. Another way of saying that is that stock is down a staggering 78.52% over the past 12 months. It's not uncommon for companies that experience equity market depreciation on par with Aurora to have cash problems and that's exactly what the Canadian cannabis company is facing.

3 Big Reasons to Avoid Beyond Meat Stock

By Marie Brodbeck, InvestorPlace Contributor
Don't get caught in the unjustified rally of Beyond Meat stock. The firm has rough waters ahead, making it a no-go for now.

3 Reasons to Stay Far Away from Pier 1 Stock

By InvestorPlace Research Staff
If you’re tempted by the discount in PIR stock, just stop. This name is cheap for a reason and it’s not going to get any better.

Will Aurora Stock Survive 2020?

By Wayne Duggan, InvestorPlace Contributor
Aurora stock has been hammered over the past year as Canadian cannabis growth has been disappointing and Aurora has failed to hit financial targets. The company just announced a major restructuring plan, but it may not be enough to stop the bleeding.

Take a Pass, Not a Hit on Aurora Stock Before Earnings

By InvestorPlace Research Staff
Aurora stock recently floundered on news that Aurora’s CEO is stepping down. It’s a significant step, but it’s also a little too late.

Expect the Recent Weakness to Continue With Qualcomm Stock

By Tom Taulli, InvestorPlace Contributor
Qualcomm stock has been in the bull mode lately, as have many other megatech stocks. But things could get tougher. The latest earnings report points to emerging issues.

Don’t Hold the Bag for GE Stock

By InvestorPlace Research Staff
GE stock enjoyed a phenomenal run in the last few months as the underlying company engages its turnaround efforts. However, huge question marks lie ahead, which means the smart money should take profits off the table.

Chesapeake Stock Is the Wrong Stock to Buy in a Greening World

By Brad Moon, InvestorPlace Contributor
Chesapeake is a hydrocarbon company in a greening world, and slowing demand for oil and natural gas is bad news for CHK stock

Despite Extreme Rally, Avoid the Bubble in Tesla Stock

By Josh Enomoto, InvestorPlace Contributor
Tesla stock continues to defy gravity, reaching crazy market valuations. But the underlying company can’t ignore the fundamentals forever.

Chesapeake Energy: The Stock Is Going From Bad To Worse

By Ian Bezek, InvestorPlace Contributor
Chesapeake Energy is trading at its lowest stock price of this century. And there's no guarantee that shares will ever recover as solvency questions loom.

Avoid FuelCell Energy Stock Even If You’re Bullish on Clean Energy

By David Moadel, InvestorPlace Contributor
There are more promising alternatives to FuelCell Energy when it comes to investments in the alternative-energy movement. Avoid FCEL stock.

Acasti Pharma Stock Is Bleeding Both Value and Credibility

By Josh Enomoto, InvestorPlace Contributor
Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.

Coronavirus Worries Will Undercut the Nio Stock Recovery

By Tom Taulli, InvestorPlace Contributor
Nio has been in the rally mode. But this is likely to fade. Here’s a look at the key reasons.

Activision Blizzard Stock Still Has a Serious Growth Problem

By Vince Martin, InvestorPlace Contributor
Activision Blizzard stock has rallied to a 52-week high, but its stagnant business suggests ATVI stock is overvalued.

There’s No Miraculous Comeback Looming for Acasti Pharma Stock

By Todd Shriber, InvestorPlace Contributor
Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with the Trilogy 1 Phase 3 trial of CaPre was that there were unanticipated levels of placebo response. Said another way, patients got a cornstarch pill, which of course would be far less expensive than any drug, and had a positive reaction to it.

Beware the Hype: Plug Power Stock Isn’t the Next Tesla

By Ian Bezek, InvestorPlace Contributor
PLUG stock has been jumping in sympathy with Tesla stock. But as the hype fades, expect PLUG's shares to sink.

Pier 1’s Struggles Mark the End of a Major Retailing Era

By Dana Blankenhorn, InvestorPlace Contributor
Pier 1 is closing half its stores and trying to become an "omni-channel" retailer, but it's about 10 years too late. Sell PIR stock now.

Alcoa Stock Likely To Remain Depressed Under Macro Concerns

By Faisal Humayun, InvestorPlace Contributor
Weak GDP growth in 2020 will translate into aluminum surplus, lower prices and pressure on margins for Alcoa stock.

Peloton Is One Battle the Short Sellers Are Winning Now

By Dana Blankenhorn, InvestorPlace Contributor
Peloton believes its video exercise service can still be a big success, but Peloton stock's enormous short ratio shows skepticism abounds.
Load More Articles